Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07141329 · ClinicalTrials.gov registry record · Phase 2
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
A Phase 2 study of Focal Onset Seizures, sponsored by Supernus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07141329: Recruiting Phase 2 study of Focal Onset Seizures, sponsored by Supernus Pharmaceuticals.
NCT07141329 is a Phase 2 study of Focal Onset Seizures that is actively recruiting participants, run by Supernus Pharmaceuticals. The registered enrollment target is 100 participants, below the 257-participant average among 4 other Focal Onset Seizures trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07141329, a Phase 2 study of Focal Onset Seizures, is actively recruiting participants, sponsored by Supernus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
Primary Outcome
The percent of participants who took at least one dose of SPN-817 and reported at least one adverse event during the 1-year SPN-817 Treatment Period
Conditions Studied
Interventions
- DRUG SPN-817
Study Locations (1)
Florida
- Medsol Clinical Research Center - Port Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
What NCT07141329 shows while recruiting
NCT07141329 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 257-participant average among 4 other Focal Onset Seizures trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Focal Onset Seizures appearing as the primary indexed condition, and to 1 intervention - of which SPN-817 is the first listed.
NCT07141329 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07141329 about?
NCT07141329 is a clinical study titled "SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures". This is a Phase 2b open-label extension study to evaluate the long-term safety and efficacy of SPN-817.
What is the current status of trial NCT07141329?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-07-30. Estimated completion is 2027-12-31.
What conditions does trial NCT07141329 study?
This clinical trial studies the following conditions: Focal Onset Seizures.
What interventions are being tested in trial NCT07141329?
The interventions under investigation include: SPN-817 (DRUG).
Who is sponsoring clinical trial NCT07141329?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07141329 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Onset Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
RECRUITING · Phase 2
-
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
COMPLETED · Phase 2
-
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
RECRUITING · Phase 3
-
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI